[{"address1": "41 South Rio Grande Street", "city": "Salt Lake City", "state": "UT", "zip": "84101", "country": "United States", "phone": "385 269 0203", "fax": "801 821 2872", "website": "https://www.recursion.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 500, "companyOfficers": [{"maxAge": 1, "name": "Mr. Naheed  Kurji", "title": "President of Canada", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Imran  Haque", "title": "Senior Vice President of AI & Digital Sciences", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ganesh Kumar Jagannathan", "title": "Chief Information Security Officer & VP of IT", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Najat  Khan", "title": "Chief R&D Officer, Chief Commercial Officer & Director", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 10, "overallRisk": 7, "governanceEpochDate": 1711929600, "maxAge": 86400, "priceHint": 2, "previousClose": 7.94, "open": 7.57, "dayLow": 7.48, "dayHigh": 7.88, "regularMarketPreviousClose": 7.94, "regularMarketOpen": 7.57, "regularMarketDayLow": 7.48, "regularMarketDayHigh": 7.88, "beta": 0.75, "forwardPE": -4.215054, "volume": 4245069, "regularMarketVolume": 4245069, "averageVolume": 6364338, "averageVolume10days": 4337950, "averageDailyVolume10Day": 4337950, "bid": 7.83, "ask": 7.86, "bidSize": 1200, "askSize": 2000, "marketCap": 1862172544, "fiftyTwoWeekLow": 4.54, "fiftyTwoWeekHigh": 16.745, "priceToSalesTrailing12Months": 41.776165, "fiftyDayAverage": 10.4756, "twoHundredDayAverage": 9.361175, "currency": "USD", "enterpriseValue": 1498788608, "floatShares": 188262320, "sharesOutstanding": 230107008, "sharesShort": 38704268, "sharesShortPriorMonth": 43520191, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.16299999, "heldPercentInsiders": 0.0558, "heldPercentInstitutions": 0.92550004, "shortRatio": 7.16, "shortPercentOfFloat": 0.2458, "impliedSharesOutstanding": 237522000, "bookValue": 1.978, "priceToBook": 3.9635997, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -328065984, "trailingEps": -1.58, "forwardEps": -1.86, "pegRatio": -0.37, "enterpriseToRevenue": 33.624, "enterpriseToEbitda": -4.602, "52WeekChange": 0.6436058, "SandP52WeekChange": 0.21080327, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RXRX", "underlyingSymbol": "RXRX", "shortName": "Recursion Pharmaceuticals, Inc.", "longName": "Recursion Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1618579800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b61b6c65-adf4-3158-aa09-6b9439d85de8", "messageBoardId": "finmb_261401243", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.84, "targetHighPrice": 17.0, "targetLowPrice": 10.0, "targetMeanPrice": 13.0, "targetMedianPrice": 12.5, "recommendationMean": 2.7, "recommendationKey": "hold", "numberOfAnalystOpinions": 6, "totalCash": 391564992, "totalCashPerShare": 1.669, "ebitda": -325657984, "totalDebt": 50672000, "quickRatio": 4.236, "currentRatio": 4.703, "totalRevenue": 44575000, "debtToEquity": 10.934, "revenuePerShare": 0.214, "returnOnAssets": -0.32294, "returnOnEquity": -0.69122005, "freeCashflow": -187367120, "operatingCashflow": -287780000, "revenueGrowth": -0.204, "grossMargins": 0.0446, "operatingMargins": -9.19273, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-26"}]